Oral Presentation details
Title:	Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154
Presenter:	Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine
Session:	Pharmaceutical Pipeline (Oral Presentation)
Date:	Tuesday, May 26, 2026
Time:	3:20 PM ET
Location:	Loews Miami Beach Hotel, Miami, FL

The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).

Poster Presentation
Date:	Wednesday, May 27, 2026
Time:	11:45 AM – 1:30 PM ET
Session:	Poster Session 1, Pharmaceutical Pipeline
Poster number:	W98

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.